Evogene (NASDAQ:EVGN – Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02, FiscalAI reports. Evogene had a negative return on equity of 156.53% and a negative net margin of 694.18%. The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.36 million.
Evogene Stock Up 2.9%
Shares of EVGN stock opened at $0.35 on Thursday. The stock has a 50 day simple moving average of $0.40 and a 200-day simple moving average of $0.62. Evogene has a 1-year low of $0.25 and a 1-year high of $1.26.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.
Read Our Latest Research Report on Evogene
Evogene Company Profile
Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.
Recommended Stories
- Five stocks we like better than Evogene
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
